Pfizer Inc vs VanEck Semiconductor ETF — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while VanEck Semiconductor ETF trades at $586.5. The key difference: Pfizer Inc pays a 6.9% dividend while VanEck Semiconductor ETF pays none, and VanEck Semiconductor ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| PFE | SMH | |
|---|---|---|
Market Cap | $142.14B | — |
Volume | 29,869,932 | — |
Sector | Health | — |
52-Week High | $28.56 | $668.91 |
52-Week Low | $23.29 | $283.95 |
Enterprise Value | $192.80B | — |
Dividend Yield | 6.9% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.
PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.
SMH trades at $584.08, up 5.08% today amid volatile semiconductor sector conditions. The ETF shows bearish technical signals with moving averages indicating selling pressure, though RSI levels suggest potential oversold conditions. Recent institutional buying by firms like Empirical Wealth Management and Assetmark Inc. contrasts with mixed news flow including China's potential AI chip export controls and concerns about AI trade rotation. The fund remains concentrated in top semiconductor names with strong AI exposure.
Outlook remains cautious as semiconductor stocks face sector rotation pressures despite strong AI demand fundamentals. Key risks include geopolitical tensions, potential capex slowdowns, and valuation concerns after the 2026 rally. The current technical setup suggests near-term consolidation between support at $538-$553 and resistance at $569-$584 levels.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →